BOTHELL, Wash., Jan. 20 /PRNewswire-FirstCall/ -- Lumera Corporation
(Nasdaq: LMRA), an emerging leader in nanotechnology solutions, named Jim
Richey as Senior Advisor, Business Development and named Dr. Charles T.
Campbell to its scientific advisory board.
"The addition of Jim Richey and Dr. Charles Campbell significantly
enables our ability to bring new, revolutionary products to market," said Tom
Mino, chief executive officer. "We are committed to building a strong,
talented and vertically integrated organization to successfully serve
biotechnology and pharmaceutical customers throughout the world."
Richey comes to Lumera with more than 25 years of experience in sales and
marketing operations in the United States, Europe and Japan. He has held
senior executive positions in numerous rapid growth biotechnology success
stories including LJL BioSystems (acquired by Molecular Devices), PerSeptive
BioSystems (acquired by Applied Biosystems, now Applera), Pharmacia Biosensor
(now BIAcore International), and Pharmacia Biotech (acquired by Amersham and
recently by General Electric, today GE Healthcare).
"As we receive orders for our first proteomics products, Jim's breadth of
experience and history of achievement will undoubtedly allow him to make an
immediate impact on the success of our company," said Tom Mino, chief
Dr. Campbell currently holds The West Endowed Professorship of Chemistry
at the University of Washington, and is co-director of the University of
Washington/Pacific Northwest National Laboratory Joint Institute for
Nanotechnology. He is currently Editor-in-Chief of the journal Surface
Science and has served on the editorial boards of the Journals of Chemical
Physics and of Cataysis. During the course of his distinguished career he has
received numerous awards and recognitions.
"Dr. Campbell brings a uniquely integrated knowledge of nanoelectronics,
surface chemistry and biodetection techniques," says Tom Mino, Lumera chief
executive officer. "We believe Dr. Campbell will have a meaningful impact as
we work toward commercialization of key Lumera technologies."
Lumera is an emerging leader in the field of nanotechnology. The company
designs proprietary molecular structures and polymer compounds for a broad
range of electro-optic, RF and specialty coating applications. The company
also has developed proprietary processes for fabricating such devices. For
more information, please visit http://www.lumera.com/.
Certain statements contained in this release are forward-looking
statements that involve a number of risks and uncertainties. Factors that
could cause actual results to differ materially from those projected in the
company's forward-looking statements include the following: market acceptance
of our technologies and products; our ability to obtain financing; our
financial and technical resources relative to those of our competitors; our
ability to keep up with rapid technological change; government regulation of
our technologies; our ability to enforce our intellectual property rights and
protect our proprietary technologies; the ability to obtain additional
contract awards and to develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products; and other risk factors identified from time to time in the
company's SEC reports, including in its registrations statement on Form S-1,
dated July 22, 2004 and its Quarterly Reports on Form 10-Q.
SOURCE Lumera Corporation